What drugs does PERRIGO PHARMA INTL make?

PERRIGO PHARMA INTL has 7 FDA-approved drugs including NASONEX 24HR ALLERGY.

What therapeutic areas does PERRIGO PHARMA INTL focus on?

PERRIGO PHARMA INTL focuses primarily on Cardiovascular and Immunology and 1 other therapeutic areas.

Data updated: Mar 10, 2026

PERRIGO PHARMA INTL

CardiovascularImmunologyGastroenterology

Specialty

PERRIGO PHARMA INTL is a specialty pharmaceutical company focused on Cardiovascular, Immunology, Gastroenterology. Key products include NASONEX 24HR ALLERGY.

2003

Since

Drugs

Trials

Approved (2yr)

Key Drugs

NASONEX 24HR ALLERGY

mometasone furoate

· 2022

Recent Activity

DICLOFENAC SODIUM 2025-12-31

Labeling

DICLOFENAC SODIUM 2025-11-05

TRIAMCINOLONE ACETONIDE 2025-10-17

TRIAMCINOLONE ACETONIDE 2025-10-08

Labeling

DICLOFENAC SODIUM 2025-09-26

Labeling

DICLOFENAC SODIUM 2025-05-21

Labeling

LORATADINE 2025-04-25

Manufacturing (CMC)

TRIAMCINOLONE ACETONIDE 2025-04-11

DICLOFENAC SODIUM 2025-04-09

TRIAMCINOLONE ACETONIDE 2025-04-03

Labeling

SEC Filings ProEarly access

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Cardiovascular 46%

1 drugs

Immunology 46%

1 drugs

Gastroenterology 8%

0 drugs Phase 1: 1

Pipeline Strength ProEarly access

Competitors ProEarly access

BAUSCH specialty

Immunology, Cardiovascular, Gastroenterology

Pfizer big-pharma

Immunology, Gastroenterology

Novartis big-pharma

Cardiovascular, Immunology

Merck big-pharma

Cardiovascular, Immunology

QUAGEN specialty

Gastroenterology, Cardiovascular, Immunology

PERRIGO PHARMA INTL

Key Drugs

Recent Activity

Therapeutic Focus

Pipeline Strength ProEarly access

Competitors ProEarly access

All Drugs (7)

Active (5)

Discontinued (2)

Company Info